Toronto, Ontario – March 17, 2022 – Magen Ventures I Inc. (TSXV:MAGN.P) (“Magen”) and Grey Wolf Animal Health Inc. (“Grey Wolf”) are pleased to announce that, further to Magen’s news release of January 26, 2022, they have entered into a business combination agreement dated March 16, 2022 (the “BCA”), which outlines the terms and conditions pursuant to which Magen and Grey Wolf will complete a transaction that will result in a reverse take-over of Magen by Grey Wolf (the “Proposed Transaction”). The Proposed Transaction will be an arm’s length transaction, and, if completed, will constitute Magen’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). Magen following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”.
Toronto, Ontario – March 17, 2022 – Magen Ventures I Inc. (TSXV:MAGN.P) (“Magen”) and Grey Wolf Animal Health Inc. (“Grey Wolf”) are pleased to announce that, further to Magen’s news release of January 26, 2022, they have entered into a business combination agreement dated March 16, 2022 (the “BCA”), which outlines the terms and conditions pursuant to which Magen and Grey Wolf will complete a transaction that will result in a reverse take-over of Magen by Grey Wolf (the “Proposed Transaction”). The Proposed Transaction will be an arm’s length transaction, and, if completed, will constitute Magen’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). Magen following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”.
Toronto, Ontario – March 17, 2022 – Magen Ventures I Inc. (TSXV:MAGN.P) (“Magen”) and Grey Wolf Animal Health Inc. (“Grey Wolf”) are pleased to announce that, further to Magen’s news release of January 26, 2022, they have entered into a business combination agreement dated March 16, 2022 (the “BCA”), which outlines the terms and conditions pursuant to which Magen and Grey Wolf will complete a transaction that will result in a reverse take-over of Magen by Grey Wolf (the “Proposed Transaction”). The Proposed Transaction will be an arm’s length transaction, and, if completed, will constitute Magen’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). Magen following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”.
Toronto, Ontario – March 17, 2022 – Magen Ventures I Inc. (TSXV:MAGN.P) (“Magen”) and Grey Wolf Animal Health Inc. (“Grey Wolf”) are pleased to announce that, further to Magen’s news release of January 26, 2022, they have entered into a business combination agreement dated March 16, 2022 (the “BCA”), which outlines the terms and conditions pursuant to which Magen and Grey Wolf will complete a transaction that will result in a reverse take-over of Magen by Grey Wolf (the “Proposed Transaction”). The Proposed Transaction will be an arm’s length transaction, and, if completed, will constitute Magen’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). Magen following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”.
Toronto, Ontario – March 17, 2022 – Magen Ventures I Inc. (TSXV:MAGN.P) (“Magen”) and Grey Wolf Animal Health Inc. (“Grey Wolf”) are pleased to announce that, further to Magen’s news release of January 26, 2022, they have entered into a business combination agreement dated March 16, 2022 (the “BCA”), which outlines the terms and conditions pursuant to which Magen and Grey Wolf will complete a transaction that will result in a reverse take-over of Magen by Grey Wolf (the “Proposed Transaction”). The Proposed Transaction will be an arm’s length transaction, and, if completed, will constitute Magen’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). Magen following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |